col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Publishing House: Publishing House OKI

57 Results       Page 1

 [1] 
  original article Journal Date Title Authors All Authors
1 [GO] Antibiotics and Chemotherapy 2022―Sep―10 Cycloferon as a Means for Prevention, Treatment, and Control of COVID-19: Multidisciplinary and Comparative Historical Aspects P. V. MAZIN, R. K. KHAFISIANOVA, V. P. MAZIN, A. A. GALKIN, A. K. OSKANOV
2 [GO] Antibiotics and Chemotherapy 2022―Sep―10 Immunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseases B. B. BELOV, N. V. MURAVYEVA, A. N. KULIKOV
3 [GO] Antibiotics and Chemotherapy 2022―Aug―07 Medical Rehabilitation of Elderly and Senior Patients with COVID-19-Associated Pneumonia M. I. Ivanova, V. M. Ivanov, Yu. M. Shcheglova, A. L. Kovalenko, E. V. Talikova
4 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2022―May―02 Lifestyle Changes in Medical Students during the COVID-19 Pandemic V. A. Sergeeva, T. E. Lipatova
5 [GO] Antibiotics and Chemotherapy 2022―Apr―16 Neuroprotective Therapy for Neurological Complications of the Novel Coronavirus Infection COVID-19 Ju. L. Lukyanova, S. A. Lukyanov, K. G. Shapovalov
6 [GO] Antibiotics and Chemotherapy 2022―Apr―16 Antibacterial Therapy of Patients With COVID-19 During The Outpatient and Hospital Stages N. A. Karoli, A. V. Aparkina, E. V. Grigoryeva, N. A. Magdeeva, N. M. Nikitina, N. D. Smirnova, A. P. Rebrov
7 [GO] Real-World Data & Evidence 2022―Mar―29 Aspects of the safe use of medicinal products based on medicinal plant materials in COVID-19 A. A. Taube
8 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2022―Feb―14 Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin
9 [GO] Pharmacogenetics and Pharmacogenomics 2022―Jan―11 Pharmacogenetics of antiviral agents for the treatment of COVID-19 I. I. Temirbulatov, A. V. Kryukov, D. A. Sychev
10 [GO] Real-World Data & Evidence 2021―Dec―06 Paracetamol safety in COVID-19 B. K. Romanov
11 [GO] Antibiotics and Chemotherapy 2021―Oct―21 Seaweed-Derived Sulfated Polysaccharides as Potential Agents for Prevention and Treatment of Influenza and COVID-19 N. N. Besednova, T. N. Zvyagintseva, B. G. Andriukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovsky, et al. (+2)
12 [GO] Antibiotics and Chemotherapy 2021―Oct―21 Problem of Drug Interactions in the Treatment of Patients with COVID-19 and Comorbid Conditions R. M. Aramisova, Z. A. Kambachokova, Z. A. Akhkubekova, L. L. Logvina, M. M. Sarbasheva, S. M. Chudopal, et al. (+4)
13 [GO] Antibiotics and Chemotherapy 2021―Oct―21 COVID-19 Therapy: the Role of Antirheumatic Drugs M. A. Litvinova, N. V. Muravyeva, B. S. Belov
14 [GO] Antibiotics and Chemotherapy 2021―Oct―21 Study of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters S. V. Chepur, A. V. Smirnova, A. N. Kirienko, I. A. Myasnikova, B. A. Kanevsky, P. V. Sorokin
15 [GO] Antibiotics and Chemotherapy 2021―Aug―30 Possibilities of suppressing the cytopathogenic effect of SARS-CoV-2 coronavirus according to the results of the antiviral activity of Cytovir®-3 in vitro study V. S. Smirnov, I. A. Leneva, T. A. Kudryavtseva, E. B. Fayzuloev, V. A. Zaplutanov, S. V. Petlenko, et al. (+3)
16 [GO] Antibiotics and Chemotherapy 2021―Aug―30 Local antiviral activity of the drug «Thymogen®», nasal dosed spray, against SARS-CoV-2 coronavirus in vitro I. A. Leneva, V. S. Smirnov, T. A. Kudryavtseva, E. B. Fayzuloev, A. V. Gracheva, N. P. Kartashova, et al. (+2)
17 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2021―Aug―13 COVID-19: economic aspects of influenza vaccine prevention E. A. Zhidkova, E. M. Gutor, Yu. A. Tkachenko, I. V. Rogova, I. A. Popova, K. G. Gurevich
18 [GO] Antibiotics and Chemotherapy 2021―Jun―25 Possibilities of Hyperinflammation Correction in COVID-19 I. S. Simutis, G. A. Boyarinov, M. Yu. Yuriev, D. S. Petrovsky, A. L. Kovalenko, S. A. Parfenov
19 [GO] Antibiotics and Chemotherapy 2021―Jun―25 Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach K. A. Zykov, E. A. Sinitsyn, A. V. Rvacheva, A. O. Bogatyreva, A. A. Zykova, T. V. Shapovalenko
20 [GO] Antibiotics and Chemotherapy 2021―Jun―25 Polyphenols Sourced from Terrestrial and Marine Plants as Coronavirus Reproduction Inhibitors N. N. Besednova, B. G. Andryukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovskiy, L. N. Fedyanina, et al. (+3)
21 [GO] Pharmacokinetics and Pharmacodynamics 2021―Jun―23 Combined oral contraception and treatment of new coronavirus infection (COVID-19): drug interaction issues O. A. Limanova, O. A. Gromova, L. E. Fedotova
22 [GO] Antibiotics and Chemotherapy 2021―May―07 The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19 А. U. Sabitov, Р. V. Sorokin, S. U. Dashutina
23 [GO] Antibiotics and Chemotherapy 2021―May―07 The Prospects of Succinates’ Use under Hypoxic Conditions in COVID-19 Yu. Р. Orlov, V. V. Afanasyev, I. A. Khilenko
24 [GO] Antibiotics and Chemotherapy 2021―May―07 Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population А. I. Zagrebneva, Е. А. Baryakh, Е. I. Zhelnova, N. G. Poteshkina, I. Р. Beloglazova, Z. Yu. Mutovina, et al. (+8)
25 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2021―Mar―12 Socioeconomic and global burden of COVID-19 A. S. Kolbin, Yu. M. Gomon, Yu. E. Balykina, D. Yu. Belousov, V. V. Strizheletskiy, I. G. Ivanov
26 [GO] Antibiotics and Chemotherapy 2021―Feb―15 Cytokine Storm in the Novel Coronavirus Infection and Methods of its Correction A. V. Ershov, V. D. Surova, V. T. Dolgikh, T. I. Dolgikh
27 [GO] Antibiotics and Chemotherapy 2021―Feb―15 Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection K. V. Kasyanenko, O. V. Maltsev, K. V. Kozlov, I. I. Lapikov, N. I. Lvov, V. S. Sukachev, et al. (+3)
28 [GO] Antibiotics and Chemotherapy 2020―Nov―23 Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19 A. U. Sabitov, V. V. Belousov, A. S. Edin, E. V. Oleinichenko, E. P. Gladunova, E. P. Tikhonova, et al. (+3)
29 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19 V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
30 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of angiotensin II receptor blockers in patients with COVID-19 A. V. Matveev, V. A. Otdelenov, D. A. Sychev
31 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibilities for the use of tofacitinib in patients with COVID-19 A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev
32 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 V. A. Otdelenov, Yu. Yu. Kiselev, K. B. Mirzaev, A. V. Matveev, D. A. Sychev
33 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibilities for the use of anakinra in COVID-19 V. A. Otdelenov, A. V. Matveev, D. A. Sychev
34 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Rationality of routine clinical use of olokizumab in COVID-19 V. M. Tsvetov, A. V. Matveev, D. A. Sychev
35 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of colchicine in patients with COVID-19 Yu. Yu. Kiselev, A. V. Matveev, D. A. Sychev
36 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of umifenovir in patients with COVID-19 Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, et al. (+6)
37 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of vitamin D3 in patients with COVID-19 I. N. Sychev, A. V. Matveev, D. A. Sychev
38 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of dipyridamole in patients with COVID-19 I. S. Burashnikova, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
39 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Dexamethasone use in patients with COVID-19 V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
40 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of remdesivir in patients with COVID-19 V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
41 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of favipiravir in patients with COVID-19 A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev
42 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Use of unlicensed drugs and off-label drug use: focus on COVID-19 S. A. Mishinova, A. A. Zhuravkov, V. K. Zhuravko
43 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge A. V. Krykov, V. A. Otdelenov, D. A. Sychev
44 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis V. M. Tsvetov, I. N. Sychev, D. A. Sychev
45 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy V. M. Tsvetov, Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev
46 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm» V. A. Otdelenov, V. M. Tsvetov, D. A. Sychev
47 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Rationale for use mefloquine for COVID-19 treatment V. A. Otdelenov, K. B. Mirzaev, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev
48 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention K. B. Mirzaev, D. A. Sychev
49 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab K. B. Mirzaev, Yu. Yu. Kiselev, D. A. Sychev
50 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Is it possible to use riamilovir to prevent infection and treat COVID-19? V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
51 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19? Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev
52 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Could canakinumab be used for COVID-19? V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
53 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibility for the use of bromhexine to prevent infection with SARS-CoV-2 K. A. Zagorodnikova, K. B. Mirzaev, D. A. Sychev
54 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―Oct―28 Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel V. A. Otdelenov, A. V. Krykov, D. A. Sychev
55 [GO] Antibiotics and Chemotherapy 2020―Jun―08 Antiviral Activity of Kagocel® in vitro Against Virus SARS-CoV-2 S. Ya. Loginova, V. N. Shchukina, S. V. Savenko, S. V. Borisevich
56 [GO] Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2020―May―30 Socio-economic burden of COVID-19 in the Russian Federation A. S. Kolbin, D. Yu. Belousov, Yu. M. Gomon, Yu. E. Balykina, I. G. Ivanov
57 [GO] Antibiotics and Chemotherapy 2020―May―25 Studying the Effectiveness of Ribavirin® in the Experimental Form of Severe Acute Respiratory Syndrome S. Ya. Loginova, V. N. Shchukina, S. V. Borisevich, R. A. Hamitov, V. A. Maksimov
 [1] 

57 Results       Page 1




[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.023 sec